Navigation Links
International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis

efinition of patients at risk of VTE and prophylaxis recommendations provided by the of Chest Physicians (ACCP) evidence-based consensus guidelines (3). The study included two categories of hospitalized patients: patients in medical wards 40 years of age or older, and patients in surgical wards, 18 years or older.

Doctor Fred Anderson, Director of the Center for Outcomes Research at the University of Massachusetts Medical School who conducted the study commented "ENDORSE is the first study to provide a global view of VTE risk and prophylaxis practices throughout the world. With more than 60,000 patients studied in more than 30 countries, the scope of ENDORSE is unprecedented. In view of the quality of the data collected and a common method to assess patients at risk for VTE and prophylaxis used, this study gives us a unique picture both globally and locally about the extent of the hospitalized patient population at risk for VTE and how these patients are managed."

ENDORSE demonstrates the high prevalence of patients at risk for VTE: 52% of hospitalized patients surveyed were at risk for VTE, corresponding to 64% of surgical patients and 42% of medical patients. The prevalence of patients at risk was consistent across the countries surveyed, demonstrating the importance of VTE risk on a global scale.

Importantly, when considering the use of recommended prophylaxis in hospitals, only 50% of hospitalized patients at risk for VTE received a method of prophylaxis recommended by the ACCP, corresponding to 59% of surgical and 40% of medical patients at risk for VTE. The use of recommended prophylaxis varied across countries; however, it was globally sub-optimal and even more so in medical than surgical patients, as the majority of medical patients at risk for VTE (60%) did not receive recommended prophylaxis.

As highlighted by Doctor Victor Tapson, Co-chair of the ENDORSE Steering Committee: "ENDORSE clearly shows that VTE is a critical safety i
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
6. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

Post Your Comments:
(Date:11/30/2009)... , BLOOMFIELD HILLS, Mich., Nov. 30 /PRNewsw...e shopping site dedicated exclusively to products ...avings Account (FSA/HSA) claims. The site is also...the-counter medications, saving shoppers up to 75 ...lthSource helps cure two common healthcare headach...
(Date:11/30/2009)... , CHICAGO, Nov. 30 MedPro ... ultrasound solutions, will showcase leading ultra...E Logiq I and Siemens X300 Premium Edition during ...of North America (RSNA) conference, being held in ...based MedPro Imaging markets ultrasound products a...
(Date:11/30/2009)... , WAYNE, N.J. and CHICAGO, Nov. 30 /PRNewsw...Annual Meeting of the Radiological Society of No...ls Inc. announced the enrollment of the first pati...o evaluate the efficacy and safety of florbetaben ...-Amyloid plaques in the brain, which are a patholo...
Breaking Medicine Technology:eHealthSource.com Launches Online Shopping Site Dedicated to Over-the Counter Medications Approved for FSA/HSA Claims 2MedPro Imaging to Showcase Leading New and Refurbished Ultrasound Solutions at RSNA 2Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 2Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 3Rural Metro Safety Net Covers County Fair 54334 1Rural Metro Safety Net Covers County Fair 54334 2Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth 54331 1Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth 54331 2Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 1Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 2Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 3Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 4
... Phase II GBM study presented at ASCO with cediran...over a quarter of patients alive,and progression- ...ewswire/ -- Data for the,investigational agent ced...l meeting of the American Society of Clinical Onco...t glioblastoma (GBM),an invasive form of brain tu...
... CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmit...II studies of pazopanib in,advanced or metastatic ...t tissue sarcoma (STS). These trials were presente...ty of Clinical Oncology,(ASCO) in Chicago. The res...rt further investigations. , Pazopanib is an oral,...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7
(Date:11/30/2009)...RNewswire-USNewswire/ -- SEIU Local 21LA members a... Sodexo will hold a rally Tuesday, Dec. 1, 2009, a...arters, 3800 Desire Parkway, New Orleans, to prote...iplinary policies that target employees who are il...dexo employees who clean schools in the Recovery S...
(Date:11/30/2009)... Harrington Physician Services (HP...ractice physicians Martin Devine, Leah Doret, Eliz...ctice. ,, These four esteemed and popular Cha...nic, will soon join the Harrington family in the n...e building under construction at 10 North Main Str...
(Date:11/30/2009)...tween the registration of a visual stimulus by the... it ― between the time we see an apple and t... behind our eyes, but by how long? And how does th..., Some estimates say the time delay lasts only 1...w study by Tel Aviv University psychologists says ...
(Date:11/30/2009)...h specially designed program, study finds , ...l, intensive early intervention program for toddle... children,s language and social skills, a new stud...ldren are able to learn and make remarkable progre...dy, published online Nov. 30 in Pediatrics , and...
(Date:11/30/2009)...d., Nov. 30 Sunlamps an...ar-round, but the ultraviolet (UV) radiation from ...Logo: http://www.newscom.com/cgi-bin/prnh/2009082...t a tan gives them a ,healthy, glow, any tan is a ..., a Food and Drug Administration (FDA) scientist a...
Breaking Medicine News(10 mins):Health News:As H1NI Hits New Orleans in Force: School Custodians to Hold Rally to Call on Contractor to Stop Penalizing Workers Coping With Illness 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 3Health News:Now you see it, now you know you see it 2Health News:Working Intensely Early on May Help Autistic Kids 2Health News:Working Intensely Early on May Help Autistic Kids 3Health News:Working Intensely Early on May Help Autistic Kids 4
...ion of Patient Advocates and Kidney Care Professio...ck of Information for Americans on,How to Manage I...onal Kidney Month, a time dedicated to educating A... access to,high-quality kidney care and create cri...
... Study Raises Caution on Using Signal Transduction... A novel drug that,fully eliminated brain tumors ...ker side -- causing permanent bone damage in young...ncers, at,least until there is a more thorough und...
...pa, Fla. - Two abstracts underscoring the importan...ovarian cancer were presented at this week,s Socie...on Women,s Cancers, by researchers from The Univer...ncer patients with non-Ashkenazi Jewish BRCA (non-...
...ON, March 10 Give an Hour, (http://www.giveanhour...fering free,mental health services to returning Ve...re now 1,000 providers, nationwide, on its network...vices are available to the service member, their i...
... LAKES, N.J., March 10 Medco Health,Solutions, In...nferences in,March as follows:, On Monday, March ...executive officer of Accredo Health Group, Inc., M... Marriott Copley,Place will begin at 1:45 p.m. ET....
...at lower risk for environmental, biological diseas... March 10 (HealthDay News) -- Children cared for b... life are more likely than those examined by diffe... covered by Medicare. All the children were born a...
Other Medicine News:Health News:Kidney Care Partners Urges Greater Kidney Disease Education and Legislative Support During National Kidney Month 2Health News:Kidney Care Partners Urges Greater Kidney Disease Education and Legislative Support During National Kidney Month 3Health News:Potential Brain Cancer Drug for Children May Damage Bones 2Health News:Potential Brain Cancer Drug for Children May Damage Bones 3Health News:Advanced-stage ovarian cancer patients with BRCA live longer, may respond better to treatment 2Health News:1,000 Mental Health Professionals Join National Network to Provide Free Counseling to Returning Veterans and their Families 2Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Continuous Doctor Care Key to Childhood Screenings 2
MAX Guard Plus
OR Guard
Flex Guard, Flexible-Back Apron
Wrap-Around Lead Apron
Medicine Products: